|
|
Anjan Aralihalli
Vice President Business Development, Intrexon Corporation
Anjan Aralihalli joined ActoGenix as Chief Business Officer in September 2013.
Anjan has over 20 years of international biopharmaceutical experience in clinical trial management, sales, marketing, operations, strategic planning and business development. Prior to ActoGeniX, he worked at Shionogi Inc., where he led the $127 Million acquisition of Victory Pharma. Between 2002-2010, he worked at Sanofi (Aventis) in both Canada and the United States in business development and strategic planning. Prior to joining Aventis, he worked in sales and marketing at Abbott Canada.
Anjan holds an MBA from Queen’s University (Canada).
|
 |
Frank J. Carillo
Chief Executive Officer, ECG Healthcare
Beyond Frank's overall management of the firm's pharmaceutical and healthcare specialty practice, he has worked with clients who must present new drug applications to FDA Advisory Committee Meetings for approval and commercial release. In doing so, ECG has achieved an impressive record of success. In the ever-changing and highly charged world of healthcare delivery and management, Frank and his partners consult and coach CEOs and senior executives of pharmaceutical companies, health care providers, experts from academia, legislators and consulting firms on strategies that address this volatile national issue.
In that capacity, Frank has been instrumental in the success of multiple FDA Advisory Committee presentations, generating a powerful record of approvals. Frank and ECG have an incomparable record of success in building the explanations and advocacy necessary for helping regulators and academicians see the benefits in new data while maintaining appropriate context around risk.
He has authored numerous articles for business and professional journals and has been featured on various national media outlets including CNN, Bloomberg, CNBC, ABC News, and Fox News. Frank is also a prominent community leader. This role extends to his work with spokespeople for several religious denominations.
Frank is a graduate of the University of Pennsylvania's Wharton School of Business and sits on the board of directors of several foundations and public companies.
|
 |
Neil Veloso
Executive Director, Technology Transfer, Johns Hopkins Technology Ventures
Neil Veloso is the Executive Director, Technology Transfer for Johns Hopkins Technology Ventures, the commercialization arm of the university. Focused on translating Johns Hopkins technology, Neil leads a team that works closely with researchers, physicians and other inventors to evaluate and protect intellectual property developed at the university. Transactionally, JHTV actively sources, negotiates, executes and enforces technology licensing agreements with both university-based startups and established companies.
Prior to joining Johns Hopkins, Neil spent nine years at Cleveland Clinic Innovations, the corporate venturing function of the healthcare system. At CCI, he was the Senior Director of Innovation Management where he lead a team based both in Cleveland and at six other academic medical centers and universities focused on technology commercialization for both Cleveland Clinic and its Innovation Alliance partners.
Neil started his technology transfer career at the Case Western Reserve University technology transfer office. He worked at two biotechnology companies, Athersys and Gliatech, on their R&D programs. Neil’s undergraduate degree is from Johns Hopkins University with a Masters of Science and Master of Business Administration from Case Western Reserve University.
|
 |
Christine T. Fischette, PhD
Chief Executive Officer, BioLinkUp, LLC
Christine T. Fischette is CEO BioLinkUp, LLC, a Corporate Strategy/Business Development Consulting entity, Senior Advisor at Griffin Securities, Inc., NY, a boutique investment banking firm, and Board member of GCA Therapeutics, a US-based conduit which seeks to in-license Western technology, pharmaceuticals and devices for the China market. She serves on private company Business/Scientific Advisory Boards for therapeutics/devices, is Chair of the M&A Committee for the Licensing Executive Society (LES), Co-Chair for the LES NYC Chapter, an invited reviewer of grant proposals at Rockefeller University to assess future development/commercialization potential, and frequently speaks on BioPharma panels at local/international meetings.
Formerly, she was President of Enzo Therapeutics, Inc., a division of Enzo Biochem (ENZ:NYSE), and has spent 25+ years in Roche, Novartis and Pfizer with increasing areas of responsibility in operational and strategic roles covering multiple therapeutic areas of drug development, commercialization and business development. She functioned as Head of Negotiation, Global Business Development & Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals where she identified, negotiated and executed multiple deals involving various deal structures, including acquisitions, with US, European, Japanese and Indian companies. She held various positions of increasing responsibility at Pfizer, NY directing preclinical/clinical development, IND’s/NDA’s, medical marketing, marketing and business development. During her tenure at Pfizer she directed the entire drug development process and subsequent marketing effort for an anti-diabetes therapy, Glucotrol XL®, and became head of Pfizer’s US commercial diabetes division.
|
 |
Richard Hoffman
Partner, WilmerHale
Mr. Hoffman is a seasoned lawyer, consultant and entrepreneur in the life sciences industry, and has significant experience in establishing new companies, negotiating and closing venture capital financings, in-licensing technologies, and developing and implementing corporate and business development strategies. Mr. Hoffman also has a successful track record in structuring, negotiating, and documenting strategic deals with both public and private companies.
From 1998 until 2013, Mr. Hoffman dedicated himself to pursuing entrepreneurial endeavors, serving as a legal advisor and business consultant to numerous biotech companies. Most recently, Mr. Hoffman was principal at R.A. Hoffman Consulting, which provided entrepreneurs and early-stage biotechnology, medical device and health care information companies with advice on corporate and business development strategies and tactics.
Mr. Hoffman began his career as an associate and, later, as junior partner at Hale and Dorr LLP. He worked in the corporate group from 1987 through 1994, representing biotechnology and medical device companies in public offerings, collaborative research arrangements, strategic alliances, intellectual property licensing and venture capital financings. In 1994, he became vice president of Finance and Business Development at Hybridon, Inc. (now a public company, Idera Pharmaceuticals) and later served in a similar role at biotech company Avitech, Inc.
|
 |
Angèle Maki
Associate Director, Business Development, Genentech
Angèle Maki is an Associate Director in Business Development at Genentech where she is responsible for developing and executing on technology in-licensing strategies. During her tenure at Genentech, she led the deals for the collaborations with Ensemble Therapeutics, OMT, Human Longevity, and 23andMe.
Prior to Genentech, Angèle was a Director in Bristol-Myers Squibb’s Strategic Transactions Group from 2009 to 2011 where she was responsible for in-licensing and out-licensing of technologies related to discovery and development of biologics. Prior to BMS, Angèle was in Business Development at Medarex, Inc., a biopharmaceutical company focused on the discovery and development of fully-human antibody therapeutics with a strong focus on cancer immunotherapy that was acquired by BMS in 2009. During her time at BMS and Medarex, she successfully negotiated numerous in- and out-licensing transactions, from early-stage research technologies to clinical-stage assets.
Angèle received a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at the Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg in Canada.
|
 |
Philippe Nore
Chief Executive Officer and Co-founder, MiNDERA Corp.
Philippe Nore is an experienced executive specialized in clinical diagnostics, genomics and life science tools. He currently is CEO and co-founder of MiNDERA, an early stage clinical diagnostics company. Before founding MiNDERA, Philippe Nore was Senior International Business Leader at Roche Diagnostics. He was responsible for the development and commercialization of the Ventana Digital Pathology products (hardware, software, algorithms to score assays) in the cancer diagnostics market, including global P&L responsibility. During his tenure at Roche he has successfully launched several FDA-approved products.
Prior to that, he was a Senior Engagement Manager at L.E.K. Consulting where he worked with CEOs of small and midsize biotech and life sciences companies. Earlier, he worked at Life Technologies where he headed Strategic Planning and Business Development for the DNA Sequencing business Unit and led the Next-Generation Sequencing taskforce. He also spent 7 years at Bain & Company where he consulted for Fortune 500 companies.
Philippe has negotiated numerous licensing and acquisition transactions in his career and has deep expertise in strategic and financial valuation of biotech assets.
Philippe holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.
|
 |
John Selig
Managing Partner, Mavericks Capital LLC
John advises life sciences companies on M&A, licensing and financial strategy. He also frequently speaks on topics in valuation, deal term benchmarking, and strategy.
Prior to joining Mavericks, John was a Managing Director at Woodside Capital Partners, a boutique investment bank. Previously, he was a Partner at Keelin Reeds Partners, a life sciences management consulting firm, where he advised dozens of VC-backed and small to mid-cap biopharmaceutical, medical device, and diagnostics companies on M&A, licensing strategies, portfolio management, valuation and strategic direction. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to inform product strategy and to provide ongoing support during deal negotiations. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.
Previously, John was a senior consultant with Strategic Decisions Group, a global management consulting firm, where he advised many of the top 20 pharmaceutical and medical device companies, as well as Fortune 500 companies in other industries on valuation, business strategy and M&A. Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa. (FINRA 79, 63)
|
 |
Robert Silverman, JD, PhD
Senior Vice President and General Counsel, Concert Pharmaceuticals, Inc.
Robert Silverman, J.D., Ph.D. has served as Senior Vice President and General Counsel to CoNCERT pharmaceuticals since December 2010 and prior to that was our Vice President and General Counsel from January 2007 to December 2010. Prior to joining Concert, he served in various legal related roles at Millennium Pharmaceuticals, Inc., a pharmaceutical company and Vertex Pharmaceuticals, a pharmaceutical company. Dr. Silverman began his legal career at FMC Corporation, a chemical manufacturing company, where he was previously a research chemist. Dr. Silverman received his J.D. from Rutgers-Camden Law School. He did postdoctoral research in organic chemistry at Stanford University after receiving a Ph.D. from the University of New Mexico and a B.A. from Lehigh University.
|
|
|
Patricia Sinatra
Managing Director, Vector Strategic Advisors
Patricia Sinatra has over 20 years of experience in the biopharmaceutical industry and has held various roles of increasing responsibility in both the commercialization and licensing of novel technologies used to treat human disease. She has worked with over 30 different companies in the biopharma space, and has experience working with many first in class-based technologies and products.
Pat has "hands-on" launch experience of novel therapeutics as well as strategic marketing and new product planning. She has developed and managed marketing campaigns, market research and developed strategies for many products. Pat also has more than 15 years of experience in the licensing function, and has negotiated or made pivotal contributions for over 15 transactions with big pharrma, biopharma and academic institutions. These include co-dev, technology licensing, and in-licensing type deals in addition to negotiating and amending agreements that were revenue driving. She has managed more than 10 revenue generating alliances.
Since 2007, Pat has also instructed and organized the annual 3-day compehensive Business Development Fundamentals Course offered through the Biotechnology Industry Organization (BIO) and the Licensing Executives Society (LES).
Pat graduated from the State University of New York where she holds a B.S. in biology with minor emphasis in chemistry and studio art, and pursued post-graduate studies in the department of microbiology at the University of Texas Southwestern Graduate School of Biomedical Sciences. She is also a dual citizen of the United States and Italy.
|
|
|
Kenneth Weber, PhD
Partner, Kilpatrick Townsend & Stockton LLP
Kenneth Weber, Ph.D., focuses his practice on patent prosecution, particularly in the areas of molecular genetics, chemistry, pharmaceuticals, plant and agricultural sciences, medical devices and microbial genetics. He regularly assists clients in patent portfolio management, due diligence reviews, validity/infringement opinions and licensing.
Dr. Weber's clients include public and private corporations across the United States. Representative corporate clients include Aqua Bounty Technologies; Avanir Pharmaceuticals, Inc.; Merrimack Pharmaceuticals, Biosensors International Group; and, Sun-Maid Growers. Representative clients in the bay area are Corcept Therapeutics, Kalobios Pharmaceuticals; QuantumScape and Sutro Biopharma.
Dr. Weber provides a unique, collaborative approach to creating patent strategies for companies with weak patent estates. Born out of years of evaluating startups for investors and creating patent prosecution strategies for clients with repurposed drugs or non-inventive medical devices, Dr. Weber’s proactive legal counsel maximizes the opportunity to extract patentable inventions from routine experimentation and engineering work.
|
 |
Michael W. Young
Vice President, Strategy, Klick Health
Michael joined PAREXEL International in late 2014. He is an accomplished, pharmaceutical and biotech executive with award-winning marketing and commercial operations credentials. He is a sought-after subject matter expert in the discipline of Alliance Management where he has honed his skills as a collaboration manager in a broad spectrum of B2B strategic partnerships and with the Association of Strategic Alliance Professionals (ASAP). He excels in building high-performance teams which extract value from collaboration initiatives, deliver on global commercial launches, and exceed partner expectations.
Prior to joining PAREXEL International, he was Vice President; Alliance Management for a different global contract research organization (CRO) His dedicated team was globally-based and oversaw top tier clients engaged in clinical development alliances. During his 4 year tenure, he also innovated and built an external vendor alliance capability for the CRO to dramatically improve client interface and results.
Michael previously pioneered a global Alliance Marketing & Management department and capability for Eisai Inc. His group managed 70 strategic B2B alliances encompassing almost $4 Billion in revenue in 27 countries. Prior to this he spent eleven years as Director of Marketing and then Executive Director, Strategic Marketing, Ligand Pharmaceuticals Inc., which was acquired by Eisai in late 2006. He was responsible for the launch of Ligand’s six product oncology and supportive care portfolio. He also managed Ligand’s international marketing activities with the company’s licensees in Europe, Latin America, and Canada. His commercial career also includes sales management, marketing, and new product development positions at GSK, Adria Laboratories, and Bayer.
Among his credentials, Michael was named Medical Marketer of the Year by the Medical Marketing Association and in 2003 served as President of the national organization. He has been an active industry speaker and author and has presented at numerous conferences including BIO, the Association of Strategic Alliance Professionals, the American Association of Pharmaceutical Sciences, the Chinese American Pharmaceutical Association, and the Drug Information Association. Michael serves on the board of directors of the Cutaneous Lymphoma Foundation and advises several other patient advocacy groups. Michael received his undergraduate degree from Kenyon College and did his graduate work at The Ohio State University.
|
